Fengting Yan. MD, PhD, FACP.

I am interested in personalized care and translational research in women’s cancer. lab & clinical research knowledge apply in my “bench-to-bedside" approach.

[Dr. Kelly Shanahan @stage4kelly]

If you have breast cancer you must watch this episode of @breastfriendspd featuring my incredible oncologist and friend Dr @hoperugo. She understands where we came from and where we are going, values supportive care as much as treatment, and I’m lucky to have her in my corner.

[Yakup Ergün @dr_yakupergun]

In 1998, the approval of trastuzumab began to change the poor prognosis of HER2-positive breast cancer for the better.

Over the following nearly 30 years, anti-HER2 therapy evolved step by step: trastuzumab, pertuzumab, T-DM1, and now T-DXd.

With the latest anti-HER2 ADC data, T-DXd has now been approved in two new indications for early-stage HER2-positive breast cancer.

First, we changed the prognosis for the better.
Now, the goal is cure...

[MV Chandrakanth @ChandrakanthMv]

T-DM1 or T-DXd after neoadjuvant therapy?

Residual HER2+ disease after NAC does not automatically mean adjuvant T-DXd.

🔹 KATHERINE → any residual invasive disease qualified for T-DM1
🔹 DESTINY-Breast05 → T-DXd studied in higher-risk residual disease

Key high-risk features in DESTINY-Breast05: • Initial cT4/cN2–3 disease
OR
• Residual nodal disease (ypN1–3)

An important eligibility distinction while interpreting adjuvant escalation strategies.

#BreastCancer #HER2positive #Oncology #MedEd #MVOnco

[Dr Sarah Sammons @drsarahsam]

Major FDA news today for early-stage HER2+ breast cancer. T-DXd approved for two separate indications: neoadjuvant Stage II/III disease (T-DXd x4 followed by THP x4), and adjuvant treatment for residual invasive disease after neoadjuvant HER2-targeted therapy.

The data are striking. DESTINY-Breast11: pCR 67.3% vs 56.3% with ddAC-THP (p=0.003). DESTINY-Breast05: 3-year IDFS 92.4% vs 83.7% with T-DM1, HR 0.47 (95% CI 0.34-0.66, p<0.0001).

But the real work is just beginning. Not every high-risk patient needs T-DXd upfront. Our challenge as oncologists is figuring out who needs what. Biomarker-driven selection, ctDNA, pCR response – these questions have to follow. Escalation and de-escalation strategies needed. #bcsm

#BCSM #BreastCancer

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

Need to add that Vepdegestrant was approved on 5/1/2026.

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

How HCPs Educate Patients on Oral SERDs in Breast Cancer: Tolerability, Expectations &amp; Adherence | Vumedi https://t.co/mhm70v8CAo via @vumedi

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Wow- big month for breast approvals so far...and it's only May 15th!

#TDXd approved for neoadjuvant and adjuvant HER-2+ #bcsm

Our @US_FDA breast colleagues have been very busy, thank you!

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

https://t.co/1bc64aY4tU

[Targeted Oncology @TargetedOnc]

In this video, Fengting Yan, MD, PhD, (@FengtingYan) discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer. #bcsm
https://t.co/9nQ0DtTq0q

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

I will be speaking at the Best of Hematology and Breast Cancer 2025 on January 3-4, 2025 in Seattle. My talk will be on 'No' for the Hrt Debate
You can register here: https://t.co/z7lINDqsWo
2

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

A new moonshot to fight cervical cancer is missing something: only one of the sponsors is within reach of the WHO’s recommendation for protecting women. We can and must to better LINK HERE:
https://t.co/jxgVdajnou

@btfoundation @binayshah @ProvSwedish @swedish @sid

[Sid Yadav MD, FACP @SidYadavMD]

Our opinion piece in @statnews highlighting the need for stronger implementation and broader access to HPV vaccination programs to end cervical cancer in the US and across the globe. Thank you @binayshah and @FengtingYan for co-authoring this.

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

@maryam_lustberg @YaleCancer Congratulations!

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

Poll, how do you pronounce foci? foe-sye or foe-kye?

[Sara Tolaney @stolaney1]

SENOMAC: SNB +/- ALND in pts with up to 2 macromets

n=2450
Median f/u 47 mo
Median tumor size 20mm (6% T3)
85% had 1 macromet
34.3% with ENE

34.5% had additional LNs on ALND (if 1 SLN 31.3%, if 2 SLN 51.3%)

No difference in 5 yr RFS 88.7% vs 89.7%

#SABCS23 @OncoAlert

[Fengting Yan. MD, PhD, FACP. @FengtingYan]

Glad to see Asian data!

[Lilly Oncology Medical @LillyOncMed]

At #SABCS23, check out our poster presentation exploring the safety profiles of Chinese breast cancer patients who received a CDK 4 &amp; 6 inhibitor in the MONARCH plus and monarchE trials.

See the data here: https://t.co/tHZRe745Dj

#bcsm #BreastCancer #CancerResearch

[Sara Tolaney @stolaney1]

IMP030: Adj chemo+/- atezo in stage 2/3 TNBC

Median f/u 25 mo
iDFS: HR 1.12, p=0.37
iDFS in PDL1+ HR 1.03

Why is there no benefit in the adjuvant setting? Is it PDL1 vs PD1 (unlikely given benefit in IMP031 preop)? Is it that there is no tumor in place?

@OncoAlert #SABCS23

[Paolo Tarantino @PTarantinoMD]

HER2CLIMB-02: The addition of tucatinib to T-DM1 significantly improved PFS (9.5 vs 7.4 months, HR 0.76, p=0.016) in patients with HER2+ MBC. OS curves look reverted (HR 1.23), though immature. Significant increase in the rate of severe liver toxicities and diarrhea. Poll below👇

[Sara Tolaney @stolaney1]

monarchE: ctDNA at baseline + 24 mo in a subset of pts

Detection of ctDNA at baseline soon after completion of neo/adjuvant tx: 10/178 (5.6%)
3 of 10 cleared ctDNA + none recurred
7 of 10 had persistence + all recurred

#SABCS23 @OncoAlert #bcsm

[Sara Tolaney @stolaney1]

MONARCH3: AI +/- abemaciclib
Final OS analysis
Median follow-up 8.1 years

66.8 vs 53.7 mo
Absolute Difference 13.1 mo
Not statistically significant

23.3% progression free at 6 yrs on the abemaciclib arm

@oncolaert #SABCS23